Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

Phase 2

Conditions: Breast Cancer
Pathological Complete Response
Neoadjuvant Chemotherapy

Interventions: Drug: Epirubicin
Drug: Fluorouracil
Drug: Docetaxel
Drug: Cyclophosphamide

First Posted Date: 2017-11-21

Last Posted Date: 2017-11-21

Lead Sponsor: Zhiyong Yu

Target Recruit Count: 200

Registration Number: NCT03349177

Maximizing Outcome of Multiple Sclerosis Transplantation

Phase 3

Terminated

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Cyclophosphamide
Drug: Mesna
Drug: rATG
Drug: Methylprednisolone
Drug: G-CSF
Biological: Autologous Stem Cells
Biological: IVIg

First Posted Date: 2017-11-17

Last Posted Date: 2021-01-11

Lead Sponsor: Northwestern University

Target Recruit Count: 66

Registration Number: NCT03342638

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Safety and Efficacy Evaluation of IM19 Cells

Phase 1

Conditions: Hematological Malignancies

Interventions: Biological: IM19 CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2017-11-17

Last Posted Date: 2017-11-17

Lead Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT03344705

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

Phase 2

Conditions: Acute Lymphoblastic Leukemia, Adult

Interventions: Drug: Gemcitabine
Drug: Busulfan
Drug: Cyclophosphamide
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date: 2017-11-13

Last Posted Date: 2020-01-14

Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Target Recruit Count: 15

Registration Number: NCT03339700

Locations: 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Leukapheresis

First Posted Date: 2017-11-09

Last Posted Date: 2023-09-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 28

Registration Number: NCT03338972

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT

Phase 2

Conditions: MDS
Leukemia, Acute

Interventions: Drug: Chidamide
Drug: Cyclophosphamide
Drug: cyclosporine A

First Posted Date: 2017-11-08

Last Posted Date: 2018-07-18

Lead Sponsor: Sichuan University

Target Recruit Count: 50

Registration Number: NCT03336632

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: cyclophosphamide

First Posted Date: 2017-11-08

Last Posted Date: 2022-09-07

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 199

Registration Number: NCT03336073

Locations: 🇪🇸
Hospital de León, León, Spain
🇪🇸
H. Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital Universitario de Santiago, Santiago De Compostela, Spain

and more 21 locations

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Phase 2

Active, not recruiting

Conditions: Acute Leukemia in Remission
Acute Myeloid Leukemia
CD40 Ligand Deficiency
Chronic Lymphocytic Leukemia
Glanzmann Thrombasthenia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Congenital Pure Red Cell Aplasia
Myelofibrosis
Paroxysmal Nocturnal Hemoglobinuria
Secondary Acute Myeloid Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2017-11-07

Last Posted Date: 2024-04-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 31

Registration Number: NCT03333486

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Phase 1

Completed

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Biological: DPX-Survivac
Drug: Cyclophosphamide
Biological: DPX-Survivac(Aqueous)

First Posted Date: 2017-11-06

Last Posted Date: 2021-06-18

Lead Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)

Target Recruit Count: 37

Registration Number: NCT03332576

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Winthrop University Hospital, Mineola, New York, United States
🇺🇸
Lenox Hill Hospital, New York, New York, United States

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Phase 2

Terminated

Conditions: Locally Advanced Breast Cancer

Interventions: Drug: Docetaxel
Drug: Pertuzumab
Drug: Carboplatin
Drug: Trastuzumab
Drug: Doxorubicin
Drug: Pegfilgrastim
Drug: Cyclophosphamide
Drug: Paclitaxel

First Posted Date: 2017-11-06

Last Posted Date: 2023-08-22

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 7

Registration Number: NCT03329378

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸
Mount Sinai West, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy